Linda Barkane

Dr. Linda Barkane

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
ZLZhiyi Lan
Zhiyi Lan
NANafees Ahmad
Nafees Ahmad
PBParvaneh Baghaei
Parvaneh Baghaei
LBLinda Barkane
Linda Barkane
ABAndrea Benedetti
Andrea Benedetti
ZUZf Udwadia
Zf Udwadia

9 November 2017 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
LKLiga Kuksa
Liga Kuksa
LBLinda Barkane
Linda Barkane
NHNorbert Hittel
Norbert Hittel
RGRajesh Gupta
Rajesh Gupta
Final treatment outcomes from the first cohort of delamanid MDR-TB patients in Latvia support its safety and efficacyhttp://ow.ly/6Mhy30fPv2f

1 February 2018 in European Respiratory Journal
Verified
Journal Article
Closed access
LGLorenzo Guglielmetti
Lorenzo Guglielmetti
LBLinda Barkane
Linda Barkane
DDDamien Le Dû
Damien Le Dû
DMDhiba Marigot-Outtandy
Dhiba Marigot-Outtandy
JRJérôme Robert
Jérôme Robert
MFMathilde Fréchet-Jachym
Mathilde Fréchet-Jachym
Good tolerability of exposure to bedaquiline-delamanid association in MDR/XDR-TB patients

Verified
Journal Article
Open access
PDF file
LFLauma Freimane
Lauma Freimane
LBLinda Barkane
Linda Barkane
AKAgnija Kivrane
Agnija Kivrane
DSDarja Sadovska
Darja Sadovska
VUViktorija Ulanova
Viktorija Ulanova
RRRenate Ranka
Renate Ranka
Following the introduction of all-oral treatment regimens for patients with drug-resistant tuberculosis (TB), second-line injectable drug applications have been reduced in the last few years. However, they are still important for anti-TB therapy. This study aims to analyze the occurrence of amikacin- and capreomycin-related adverse drug reactions (ADR) in patients with multidrug-resistant tuberculosis (MDR-TB) and evaluate the role of multiple patient-, disease-, and therapy-related factors on the frequency of the observed adverse events. In addition, the possible role of genetic risk factors was studied by full-length mitochondrial DNA sequencing. Toward this aim, we retrospectively evaluated 47 patients with MDR-TB who received amikacin and/or capreomycin. In total, 16 (34.0%) patients developed ototoxicity and 13 (27.7%) developed nephrotoxicity, including 3 (6.4%) patients who experienced both adverse events. Ototoxicity development was more common in patients who received amikacin. No other factors showed a significant impact. Nephrotoxicity was likely associated with previous renal health impairment. Full mitochondrial genome sequencing did not reveal any specific ADR-associated variants, and results showed no differences in adverse event occurrence for any specific variants, mutation count, or mitochondrial haplogroup. The absence of the previously reported ototoxicity-related mtDNA variants in our patients with ototoxicity and nephrotoxicity highlighted the complex nature of the ADR occurrence.